TY - JOUR
T1 - Attitudes toward and experience with naloxone among people who use drugs in the Southeastern United States
AU - Le, Mylinh H.
AU - Laschober, Tanja C.
AU - Tross, Susan
AU - Paschen-Wolff, Margaret
AU - Ertl, Melissa M.
AU - Wright, Lynette
AU - Hatch, Mary A.
N1 - Publisher Copyright:
© 2025 Elsevier B.V.
PY - 2025/5
Y1 - 2025/5
N2 - Background: The opioid epidemic presses on as a significant public health issue in the U.S., with particularly high overdose death rates in the Southeast. Naloxone is the standard of care for reversing opioid overdose; however, many people who use drugs (PWUD) experience barriers to naloxone use. This cross-sectional survey study aims to describe awareness of, experience with, willingness, barriers, and distribution strategies for naloxone among PWUD in the Southeast. Methods: Data were obtained from a larger implementation survey study. Descriptive analyses focused on N = 381 people in substance use treatment programs, syringe services programs, and sexually transmitted infection clinics who reported non-prescription opioid use in the past 12 months and completed a naloxone-related questionnaire. Results: Most PWUD reported using opioids daily (60–62 %). 82 % had previously heard of naloxone, but only 43 % reported having received any type of training to use it. On a 5-point scale, PWUD without prior training (n = 219) reported being very willing to be trained to use naloxone on someone who overdoses (Mdn=5.00, IQR=2.00). Among all PWUD, not knowing where to go for naloxone training was the only barrier to using naloxone that was endorsed with certainty (Mdn=4.00, IQR=2.00). PWUD endorsed three strategies to improve naloxone distribution, including wanting their site to offer naloxone training (Mdn=4.00, IQR=1.00), increased access to naloxone education (Mdn=4.00, IQR=1.00), and connecting people to training programs (Mdn=4.00, IQR=1.00). Conclusion: This study suggests that improvements are still needed in the saturation of naloxone training and distribution among PWUD, including in settings that provide non-opioid related services.
AB - Background: The opioid epidemic presses on as a significant public health issue in the U.S., with particularly high overdose death rates in the Southeast. Naloxone is the standard of care for reversing opioid overdose; however, many people who use drugs (PWUD) experience barriers to naloxone use. This cross-sectional survey study aims to describe awareness of, experience with, willingness, barriers, and distribution strategies for naloxone among PWUD in the Southeast. Methods: Data were obtained from a larger implementation survey study. Descriptive analyses focused on N = 381 people in substance use treatment programs, syringe services programs, and sexually transmitted infection clinics who reported non-prescription opioid use in the past 12 months and completed a naloxone-related questionnaire. Results: Most PWUD reported using opioids daily (60–62 %). 82 % had previously heard of naloxone, but only 43 % reported having received any type of training to use it. On a 5-point scale, PWUD without prior training (n = 219) reported being very willing to be trained to use naloxone on someone who overdoses (Mdn=5.00, IQR=2.00). Among all PWUD, not knowing where to go for naloxone training was the only barrier to using naloxone that was endorsed with certainty (Mdn=4.00, IQR=2.00). PWUD endorsed three strategies to improve naloxone distribution, including wanting their site to offer naloxone training (Mdn=4.00, IQR=1.00), increased access to naloxone education (Mdn=4.00, IQR=1.00), and connecting people to training programs (Mdn=4.00, IQR=1.00). Conclusion: This study suggests that improvements are still needed in the saturation of naloxone training and distribution among PWUD, including in settings that provide non-opioid related services.
KW - Fentanyl
KW - Naloxone
KW - Opioid overdose
KW - People who use drugs
KW - Substance use
UR - http://www.scopus.com/inward/record.url?scp=86000540910&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=86000540910&partnerID=8YFLogxK
U2 - 10.1016/j.drugpo.2025.104769
DO - 10.1016/j.drugpo.2025.104769
M3 - Article
C2 - 40073718
AN - SCOPUS:86000540910
SN - 0955-3959
VL - 139
JO - International Journal of Drug Policy
JF - International Journal of Drug Policy
M1 - 104769
ER -